{"id":745789,"date":"2018-01-03T06:45:00","date_gmt":"2018-01-03T06:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2\/"},"modified":"2025-11-07T01:27:32","modified_gmt":"2025-11-07T06:27:32","slug":"merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2\/","title":{"rendered":"Merck to Hold Fourth-Quarter and Full-Year 2017 Sales and Earnings Conference Call on February 2"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      will hold its fourth-quarter and full-year 2017 sales and earnings<br \/>\n      conference call with institutional investors and analysts at 8:00 a.m.<br \/>\n      EST on Friday, February 2. During the call, company executives will<br \/>\n      provide an overview of Merck\u2019s performance for the quarter and year.\n    <\/p>\n<p>\n      Investors, journalists and the general public may access a live audio<br \/>\n      webcast of the call on Merck\u2019s website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Finvestors.merck.com%2Finvestors%2Fwebcasts-and-presentations%2Fdefault.aspx&amp;esheet=51736897&amp;newsitemid=20180103005189&amp;lan=en-US&amp;anchor=http%3A%2F%2Finvestors.merck.com%2Finvestors%2Fwebcasts-and-presentations%2Fdefault.aspx&amp;index=1&amp;md5=9ec042b203f5b10a7b6d704c33dea9e8\" rel=\"nofollow\">http:\/\/investors.merck.com\/investors\/webcasts-and-presentations\/default.aspx<\/a>.<br \/>\n      A replay of the webcast, along with the sales and earnings news release<br \/>\n      and supplemental financial disclosures, will be available at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51736897&amp;newsitemid=20180103005189&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=668e8f415af1500eb31ab21c31d3948b\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>.\n    <\/p>\n<p>\n      Institutional investors and analysts can participate in the call by<br \/>\n      dialing (706) 758-9927 or (877) 381-5782 and using ID code number<br \/>\n      9899537. Members of the media are invited to monitor the call by dialing<br \/>\n      (706) 758-9928 or (800) 399-7917 and using ID code number 9899537.<br \/>\n      Journalists who wish to ask questions are requested to contact a member<br \/>\n      of Merck\u2019s Media Relations team at the conclusion of the call.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51736897&amp;newsitemid=20180103005189&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=a844a68fce49672a37610830ed5e821e\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and\u00a0connect with us on\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51736897&amp;newsitemid=20180103005189&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=4920c25752e1900af32bc32709f64de0\" rel=\"nofollow\">Twitter<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51736897&amp;newsitemid=20180103005189&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=0b25603da83277b1d0d637f753b980f5\" rel=\"nofollow\">Facebook<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51736897&amp;newsitemid=20180103005189&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=f2468db7c23dec39de390f23a29355ec\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51736897&amp;newsitemid=20180103005189&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=93133b669b2cef20d2419d6f293adf47\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51736897&amp;newsitemid=20180103005189&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=8&amp;md5=9484173ee7ab3895c9b39e075307b09b\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. If underlying assumptions prove<br \/>\n      inaccurate or risks or uncertainties materialize, actual results may<br \/>\n      differ materially from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51736897&amp;newsitemid=20180103005189&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=4097508387811dd891c0a20963eed647\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180103005189r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Claire Gillespie, 267-305-0932<br \/>or<br \/>Investors:<br \/>Teri        Loxam, 908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2017 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Friday, February 2. During the call, company executives will provide an overview of Merck\u2019s performance for the quarter and year. Investors, journalists and the general public may access a live audio webcast of the call on Merck\u2019s website at http:\/\/investors.merck.com\/investors\/webcasts-and-presentations\/default.aspx. A replay of the webcast, along with the sales and earnings news release and supplemental financial disclosures, will be available at vip2-msd.com\/merckcom-migrated. Institutional investors and analysts can participate in the call by dialing (706) 758-9927 or (877) 381-5782 and using ID code number 9899537. Members of the media are invited to monitor the call by dialing (706) 758-9928 or (800) 399-7917 and using ID code number 9899537. Journalists who wish to ask questions are<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,52,64,289],"class_list":["post-745789","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-financial-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck to Hold Fourth-Quarter and Full-Year 2017 Sales and Earnings Conference Call on February 2 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to Hold Fourth-Quarter and Full-Year 2017 Sales and Earnings Conference Call on February 2 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2017 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Friday, February 2. During the call, company executives will provide an overview of Merck\u2019s performance for the quarter and year. Investors, journalists and the general public may access a live audio webcast of the call on Merck\u2019s website at http:\/\/investors.merck.com\/investors\/webcasts-and-presentations\/default.aspx. A replay of the webcast, along with the sales and earnings news release and supplemental financial disclosures, will be available at vip2-msd.com\/merckcom-migrated. Institutional investors and analysts can participate in the call by dialing (706) 758-9927 or (877) 381-5782 and using ID code number 9899537. Members of the media are invited to monitor the call by dialing (706) 758-9928 or (800) 399-7917 and using ID code number 9899537. Journalists who wish to ask questions are\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2\\\/\",\"name\":\"Merck to Hold Fourth-Quarter and Full-Year 2017 Sales and Earnings Conference Call on February 2 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-01-03T06:45:00+00:00\",\"dateModified\":\"2025-11-07T06:27:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck to Hold Fourth-Quarter and Full-Year 2017 Sales and Earnings Conference Call on February 2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck to Hold Fourth-Quarter and Full-Year 2017 Sales and Earnings Conference Call on February 2 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2\/","og_locale":"en_US","og_type":"article","og_title":"Merck to Hold Fourth-Quarter and Full-Year 2017 Sales and Earnings Conference Call on February 2 - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2017 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Friday, February 2. During the call, company executives will provide an overview of Merck\u2019s performance for the quarter and year. Investors, journalists and the general public may access a live audio webcast of the call on Merck\u2019s website at http:\/\/investors.merck.com\/investors\/webcasts-and-presentations\/default.aspx. A replay of the webcast, along with the sales and earnings news release and supplemental financial disclosures, will be available at vip2-msd.com\/merckcom-migrated. Institutional investors and analysts can participate in the call by dialing (706) 758-9927 or (877) 381-5782 and using ID code number 9899537. Members of the media are invited to monitor the call by dialing (706) 758-9928 or (800) 399-7917 and using ID code number 9899537. Journalists who wish to ask questions are","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:32+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2\/","name":"Merck to Hold Fourth-Quarter and Full-Year 2017 Sales and Earnings Conference Call on February 2 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-01-03T06:45:00+00:00","dateModified":"2025-11-07T06:27:32+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-hold-fourth-quarter-and-full-year-2017-sales-and-earnings-conference-call-on-february-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck to Hold Fourth-Quarter and Full-Year 2017 Sales and Earnings Conference Call on February 2"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"b3eb746e-9279-4403-9607-301b3cab4a27","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745789\/revisions"}],"predecessor-version":[{"id":3675146,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745789\/revisions\/3675146"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745789"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}